Quadrature Capital’s Passage Bio PASG Stock Holding History

Quadrature Capital’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,578	Closed	-$148K	–	1732
2025 Q4	$148K	Buy	+12,578	New	+$109K	﹤0.01%	1031

Other funds holding PASG

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Quadrature Capital's PASG Position: Q1 2026 in Review

Quadrature Capital sold out of Passage Bio (PASG) in Q1 2026, closing a stake of 12,578 shares — an estimated $148K sold.

Quadrature Capital first reported a position in PASG in Q4 2025 and held it in 1 quarter. The position peaked at $148K in Q4 2025. 35 funds tracked by Wall St. Rank hold PASG as of Q1 2026.

Quadrature Capital reported no remaining Passage Bio position as of Q1 2026 after selling out during the quarter.
Quadrature Capital sold 12,578 Passage Bio shares in Q1 2026, an estimated $148K.
Quadrature Capital first reported a position in Passage Bio in Q4 2025 and held it in 1 quarter.
Quadrature Capital's Passage Bio position peaked at $148K in Q4 2025.
35 funds tracked by Wall St. Rank held Passage Bio as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.